Brain-derived neurotrophic factor in patients with Huntington's disease |
|
Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice |
|
Disruption of astrocyte-neuron cholesterol cross talk affects neuronal function in Huntington's disease. |
|
Early and brain region-specific decrease of de novo cholesterol biosynthesis in Huntington's disease: A cross-validation study in Q175 knock-in mice |
|
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses |
|
Evaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell model |
|
An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin |
|
From microarray analysis to a potential dysfunction of cholesterol biosynthetic pathway in Huntington's disease : corso di dottorato di ricerca in scienze farmacotossicologiche, farmacognostiche e biotecnologie farmacologiche, ciclo 18. : tesi di dottorato di ricerca / Marta Valenza ; tutor: Elena Cattaneo ; coordinatore: Guido Franceschini |
|
A gene network regulating lysosomal biogenesis and function |
|
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes |
|
In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system |
|
Lack of huntingtin promotes neural stem cells differentiation into glial cells while neurons expressing huntingtin with expanded polyglutamine tracts undergo cell death |
|
Loss of huntingtin function complemented by small molecules acting as repressor element 1/neuron restrictive silencer element silencer modulators |
|
Molecular mechanisms and potential therapeutical targets in Huntington's disease |
|
Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington's disease |
|
Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. |
|
Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease |
|
Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery |
|
Striatal infusion of cholesterol promotes dose-dependent behavioral benefits and exerts disease-modifying effects in Huntington's disease mice |
|
Whole body cholesterol metabolism is impaired in Huntington's disease. |
|